同位素2024,Vol.37Issue(5) :423-430.DOI:10.7538/tws.2024.youxian.031

联硒透明质酸的制备及其在射线辐照下对肿瘤的联合治疗评价

Preparation of Diselenide-Hyaluronic Acid and Evaluation of Its Tumor Therapy Effect Under Irradiation

阚文涛 杨宇川 杨夏 涂俊 魏洪源 黄曾
同位素2024,Vol.37Issue(5) :423-430.DOI:10.7538/tws.2024.youxian.031

联硒透明质酸的制备及其在射线辐照下对肿瘤的联合治疗评价

Preparation of Diselenide-Hyaluronic Acid and Evaluation of Its Tumor Therapy Effect Under Irradiation

阚文涛 1杨宇川 1杨夏 1涂俊 1魏洪源 1黄曾1
扫码查看

作者信息

  • 1. 中国工程物理研究院核物理与化学研究所,四川绵阳,621900
  • 折叠

摘要

为提高抗肿瘤药物的效力及生物相容性,本研究开发了联硒透明质酸作为在射线辐照下的肿瘤联合治疗药物.在对正常细胞的毒性评价中发现,采用适当分子量的透明质酸复合联硒基团可减小药物毒性.在低治疗剂量 4Gy的射线辐照下,短时间内可达到对肿瘤的显著治疗效果,实现肿瘤细胞存活率 30%所需要的药物浓度仅为 27 μg/mL.以上结果表明,本研究开发的联硒透明质酸可为在射线辐照条件下对肿瘤的治疗提供更有效方案.

Abstract

In order to enhance the drug anti-tumor efficacy and biocompatibility,diselenide-hyaluronic acid has been developed as tumor therapy drug under irradiation in this research.In cellular toxicity evaluation,we observed that the introduction of hyaluronic acid had reduced the toxicity of diselenide agent.Under low therapeutic irradiation dose 4 Gy,remarkable anti-tumor effect has been realized,which tumor cellular viability can be realized with the drug concentration of only 27 μg/mL.The diselenide-hyaluronic acid developed in this research can provide an effective tumor therapy protocol under irradiation.

关键词

联硒/透明质酸/辐照/肿瘤治疗/亚硒酸

Key words

diselenide/hyaluronic acid/irradiation/tumor therapy/seleninic acid

引用本文复制引用

出版年

2024
同位素
中国核学会同位素分会

同位素

CSTPCD
影响因子:0.405
ISSN:1000-7512
段落导航相关论文